Gilead Sciences, Inc. $GILD Stock Holdings Increased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 427.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 266,845 shares of the biopharmaceutical company’s stock after purchasing an additional 216,275 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Gilead Sciences were worth $33,713,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC increased its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $26,000. Wealth Preservation Advisors LLC raised its holdings in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the fourth quarter valued at $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $138.14 on Friday. The firm has a market capitalization of $171.29 billion, a PE ratio of -51.74 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm’s fifty day simple moving average is $129.93 and its 200 day simple moving average is $136.44.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The business’s revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock worth $6,568,860 in the last 90 days. 0.30% of the stock is owned by company insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong Q2 operating trends: Analysts highlighted continued year-over-year sales growth led by Biktarvy and the HIV prevention franchise. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy and Livdelzi contributed to growth in oncology and liver disease. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI oncology collaboration: Gilead partnered with Nucleai to apply AI-powered tissue analytics to its antibody-drug conjugate programs. The technology could accelerate biomarker discovery and support more precise development of Gilead’s oncology pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Partnership and pipeline optionality: Gilead’s collaboration with Merck is being viewed as a potential growth engine, with recent clinical and regulatory progress supporting the strategic value of combining the companies’ capabilities. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Positive Sentiment: Assembly Biosciences collaboration: Assembly expanded development of ABI-6250 and reported a $115 million financing, while its cash runway includes a Gilead collaboration extension. The update supports continued advancement of programs associated with Gilead’s partnership. Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
• Positive Sentiment: Analyst and options signals: Analysts cited a consensus price target of $158.04, above the recent trading level, while unusually high call-option activity reflected increased bullish interest. Investors Purchase High Volume of Gilead Sciences Call Options Gilead Receives Consensus Target Price
• Neutral Sentiment: Valuation remains a debate: Despite a substantial multiyear return, commentary suggests Gilead still appears reasonably valued based on sales, leaving room for further gains if growth initiatives continue. Gilead Stock Still Looks Cheap on Sales
• Negative Sentiment: Mixed earnings-estimate revisions: Erste Group Bank modestly reduced its FY2026 EPS forecast to $(0.75) from $(0.74), below the broader consensus estimate of $(0.53), signaling some caution around near-term profitability. Erste Group Bank Estimates Gilead Sciences FY2027 Earnings

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GILD. The Goldman Sachs Group boosted their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 20th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.